Cargando…

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics

BACKGROUND: Metastatic prostate cancer is a common and lethal disease for which there are no therapies that produce cures or long‐term durable remissions. Clinically relevant preclinical models are needed to increase our understanding of biology of this malignancy and to evaluate new agents that mig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Holly M., Vessella, Robert L., Morrissey, Colm, Brown, Lisha G., Coleman, Ilsa M., Higano, Celestia S., Mostaghel, Elahe A., Zhang, Xiaotun, True, Lawrence D., Lam, Hung‐Ming, Roudier, Martine, Lange, Paul H., Nelson, Peter S., Corey, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354949/ https://www.ncbi.nlm.nih.gov/pubmed/28156002 http://dx.doi.org/10.1002/pros.23313

Ejemplares similares

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer
por: Kumar, Akash, et al.
Publicado: (2016)

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature
por: Labrecque, Mark P., et al.
Publicado: (2021)

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
por: Morrissey, Colm, et al.
Publicado: (2007)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
por: Ruppender, Nazanin, et al.
Publicado: (2015)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
por: Pritchard, Colin C., et al.
Publicado: (2014)

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
por: Brady, Lauren, et al.
Publicado: (2021)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes
por: Gordon, Ryan R., et al.
Publicado: (2014)

Single cell transcriptomic analysis of prostate cancer cells
por: Welty, Christopher J, et al.
Publicado: (2013)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

Steroid hormone synthetic pathways in prostate cancer
por: Mostaghel, Elahe A.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
por: Patel, Radhika A., et al.
Publicado: (2022)

Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021)

Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors
por: Cherrier, Monique M., et al.
Publicado: (2021)

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
por: Sychev, Zoi E., et al.
Publicado: (2023)

Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach
por: Bossio, Jennifer A., et al.
Publicado: (2021)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways
por: Chéry, Lisly, et al.
Publicado: (2014)

SAT-114 Loss of DHEA-Targeting SULT2b1b Sulfotransferase Exacerbates Aggressive Traits of Prostate Cancer
por: Song, Chung Seog, et al.
Publicado: (2020)

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
por: Sayar, Erolcan, et al.
Publicado: (2023)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Assessing the nutritional needs of men with prostate cancer
por: McLaughlin, Kaitlin, et al.
Publicado: (2019)

Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
por: Graff, Julie N, et al.
Publicado: (2015)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
por: Bhatia, Vipul, et al.
Publicado: (2023)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
por: Mostaghel, Elahe A
Publicado: (2014)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions
por: Mohammad, Osama S., et al.
Publicado: (2017)

Combination of [(177)Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
por: Simón, Marina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g5626otikcuqmfg960dpm80lov